Clinical Trial Update: Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase III randomized, double-blind, placebo-controlled trial evaluating intravenous immunoglobulin for multiple sclerosis has completed. The document notes the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Intravenous Immunoglobulin (IVIG)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED